{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T14:59:32Z","timestamp":1726412372336},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Herz"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00059-021-05054-x","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T14:02:48Z","timestamp":1630936968000},"page":"485-496","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Kardiale Amyloidose und Aortenklappenstenose","Cardiac amyloidosis and aortic valve stenosis"],"prefix":"10.1007","volume":"46","author":[{"given":"Sophiko","family":"Erbel-Khurtsidze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rainer","family":"Seibel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Detlef","family":"Moka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka\ufefft\ufeffj\ufeffa\ufeff","family":"Brandt\ufeff-\ufeffMainz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Erbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur","family":"Lichtenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"issue":"4","key":"5054_CR1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","volume":"110","author":"A Yilmaz","year":"2021","unstructured":"Yilmaz\u00a0A, Bauersachs\u00a0J, Bengel\u00a0F et\u00a0al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German cardiac society (DGK). Clin Res Cardiol 110(4):479\u2013506","journal-title":"Clin Res Cardiol"},{"issue":"16","key":"5054_CR2","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","volume":"42","author":"P Garcia-Pavia","year":"2021","unstructured":"Garcia-Pavia\u00a0P, Rapezzi\u00a0C, Adler\u00a0Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart\u00a0J 42(16):1554\u20131568. https:\/\/doi.org\/10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"issue":"6","key":"5054_CR3","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini\u00a0G, Bellotti\u00a0V (2003) Molecular mechanisms of amyloidosis. N\u00a0Engl J Med 349(6):583\u2013596","journal-title":"N Engl J Med"},{"issue":"14","key":"5054_CR4","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","volume":"29","author":"G Merlini","year":"2011","unstructured":"Merlini\u00a0G, Seldin\u00a0DC, Gertz\u00a0MA (2011) Amyloidosis: pathogenesis and new therapeutic options. J\u00a0Clin Oncol 29(14):1924\u20131933","journal-title":"J Clin Oncol"},{"issue":"5","key":"5054_CR5","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1097\/HCO.0000000000000547","volume":"33","author":"J Nativi-Nicolau","year":"2018","unstructured":"Nativi-Nicolau\u00a0J, Maurer\u00a0MS (2018) Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol 33(5):571\u2013579","journal-title":"Curr Opin Cardiol"},{"issue":"9","key":"5054_CR6","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.recesp.2011.05.003","volume":"64","author":"P Garc\u00eda-Pav\u00eda","year":"2011","unstructured":"Garc\u00eda-Pav\u00eda\u00a0P, Tom\u00e9-Esteban\u00a0MT, Rapezzi\u00a0C (2011) Amiloidosis. Tambi\u00e9n una enfermedad del coraz\u00f3n. Rev Esp Cardiol 64(9):797\u2013808","journal-title":"Rev Esp Cardiol"},{"key":"5054_CR7","first-page":"2346","volume":"12","author":"M Fotana","year":"2019","unstructured":"Fotana\u00a0M, Corovic\u00a0A, Scully\u00a0P, Moon\u00a0JC (2019) Myocardial amyloidosis. The exemplar interstitial disease. JACC Cardiovasc Imaging 12:2346\u20132356","journal-title":"JACC Cardiovasc. Imaging"},{"issue":"5","key":"5054_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCHEARTFAILURE.109.853697","volume":"2","author":"DC Christoph","year":"2009","unstructured":"Christoph\u00a0DC, Boese\u00a0D, Johnson\u00a0KT et\u00a0al (2009) Heart failure and cardiac involvement as isolated manifestation of familial form of transthyretin amyloidosis resulting from Val30Met mutation with no clinical signs of polyneuropathy. Circ Heart Fail 2(5):512\u2013515","journal-title":"Circ Heart Fail"},{"issue":"7","key":"5054_CR9","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/eurheartj\/ehs123","volume":"34","author":"C Rapezzi","year":"2013","unstructured":"Rapezzi\u00a0C, Quarta\u00a0CC, Obici\u00a0L et al (2013) Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: an Italian perspective. Eur Heart\u00a0J 34(7):520\u2013528","journal-title":"Eur Heart J"},{"issue":"9","key":"5054_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11886-019-1180-2","volume":"21","author":"L Chacko","year":"2019","unstructured":"Chacko\u00a0L, Martone\u00a0R, Cappelli\u00a0F, Fontana\u00a0M (2019) Cardiac amyloidosis: updates in imaging. Curr Cardiol Rep 21(9):108","journal-title":"Curr Cardiol Rep"},{"issue":"21","key":"5054_CR11","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jacc.2019.09.056","volume":"74","author":"J Ternacle","year":"2019","unstructured":"Ternacle\u00a0J, Krapf\u00a0L, Mohty\u00a0D et\u00a0al (2019) Aortic stenosis and cardiac amyloidosis: JACC review topic of the week. J\u00a0Am Coll Cardiol 74(21):2638\u20132651","journal-title":"J Am Coll Cardiol"},{"issue":"23\u201324","key":"5054_CR12","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s00508-020-01781-z","volume":"132","author":"D Bonderman","year":"2020","unstructured":"Bonderman\u00a0D, P\u00f6lzl\u00a0G, Ablasser\u00a0K et\u00a0al (2020) Diagnosis and treatment of cardiac amyloidosis: an interdisciplinary consensus statement. Wien Klin Wochenschr 132(23\u201324):742\u2013761","journal-title":"Wien Klin Wochenschr"},{"issue":"4","key":"5054_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.carpath.2009.04.005","volume":"19","author":"AV Kristen","year":"2010","unstructured":"Kristen\u00a0AV, Schnabel\u00a0PA, Winter\u00a0B et\u00a0al (2010) High prevalence of amyloid in 150 surgically removed heart valves\u2014a comparison of histological and clinical data reveals a\u00a0correlation to atheroinflammatory conditions. Cardiovasc Pathol 19(4):228\u2013235","journal-title":"Cardiovasc Pathol"},{"issue":"8","key":"5054_CR14","doi-asserted-by":"publisher","first-page":"e005066","DOI":"10.1161\/CIRCIMAGING.116.005066","volume":"9","author":"TA Treibel","year":"2016","unstructured":"Treibel\u00a0TA, Fontana\u00a0M, Gilbertson\u00a0JA et\u00a0al (2016) Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 9(8):e5066","journal-title":"Circ Cardiovasc Imaging"},{"issue":"47","key":"5054_CR15","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","volume":"37","author":"A Galat","year":"2016","unstructured":"Galat\u00a0A, Guellich\u00a0A, Bodez\u00a0D et\u00a0al (2016) Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart\u00a0J 37(47):3525\u20133531","journal-title":"Eur Heart J"},{"issue":"3","key":"5054_CR16","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.jcmg.2015.04.012","volume":"9","author":"S Longhi","year":"2016","unstructured":"Longhi\u00a0S, Lorenzini\u00a0M, Gagliardi\u00a0C et al (2016) Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis. JACC Cardiovasc Imaging 9(3):325\u2013327","journal-title":"JACC Cardiovasc Imaging"},{"issue":"38","key":"5054_CR17","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","volume":"38","author":"A Casta\u00f1o","year":"2017","unstructured":"Casta\u00f1o\u00a0A, Narotsky\u00a0DL, Hamid\u00a0N et\u00a0al (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart\u00a0J 38(38):2879\u20132887","journal-title":"Eur Heart J"},{"issue":"29","key":"5054_CR18","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1093\/eurheartj\/ehaa170","volume":"41","author":"PR Scully","year":"2020","unstructured":"Scully\u00a0PR, Patel\u00a0KP, Treibel\u00a0TA et\u00a0al (2020) Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation. Eur Heart\u00a0J 41(29):2759\u20132767","journal-title":"Eur Heart J"},{"issue":"17","key":"5054_CR19","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.jacc.2018.07.092","volume":"72","author":"BW Sperry","year":"2018","unstructured":"Sperry\u00a0BW, Reyes\u00a0BA, Ikram\u00a0A et\u00a0al (2018) Tenosynovial and cardiac amyloidosis in patients undergoing carpal tunnel release. J\u00a0Am Coll Cardiol 72(17):2040\u20132050","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"5054_CR20","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1001\/jama.2017.9236","volume":"318","author":"HI Geller","year":"2017","unstructured":"Geller\u00a0HI, Singh\u00a0A, Alexander\u00a0KM, Mirto\u00a0TM, Falk\u00a0RH (2017) Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis. JAMA 318(10):962\u2013963","journal-title":"JAMA"},{"issue":"3","key":"5054_CR21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/03009734.2014.895786","volume":"119","author":"P Westermark","year":"2014","unstructured":"Westermark\u00a0P, Westermark\u00a0GT, Suhr\u00a0OB, Berg\u00a0S (2014) Transthyretin-derived amyloidosis: probably a\u00a0common cause of lumbar spinal stenosis. Ups J Med Sci 119(3):223\u2013228","journal-title":"Ups J Med Sci"},{"key":"5054_CR22","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.wneu.2019.07.172","volume":"131","author":"RS Dowd","year":"2019","unstructured":"Dowd\u00a0RS, Nail\u00a0TJ, Arkun\u00a0K et\u00a0al (2019) Where neurosurgery meets heart failure: a\u00a0case report of a\u00a0patient with amyloid transthyretin wild type in the ligamentum flavum and cardiac tissue with bilateral carpal tunnel syndrome. World Neurosurg 131:104\u2013107","journal-title":"World Neurosurg"},{"issue":"2","key":"5054_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/13506129.2017.1330744","volume":"24","author":"E B\u00e9quignon","year":"2017","unstructured":"B\u00e9quignon\u00a0E, Guellich\u00a0A, Bartier\u00a0S et al (2017) How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss in elderly-AmyloDEAFNESS pilot study. Amyloid 24(2):96\u2013100","journal-title":"Amyloid"},{"issue":"2","key":"5054_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","volume":"77","author":"C Nitsche","year":"2021","unstructured":"Nitsche\u00a0C, Scully\u00a0PR, Patel\u00a0KP et\u00a0al (2021) Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J\u00a0Am Coll Cardiol 77(2):128\u2013139","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5054_CR25","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.jelectrocard.2017.04.016","volume":"50","author":"DH Kim","year":"2017","unstructured":"Kim\u00a0DH, Verdino\u00a0RJ (2017) Electrocardiogram voltage discordance: interpretation of low QRS voltage only in the precordial leads. J\u00a0Electrocardiol 50(5):551\u2013554","journal-title":"J Electrocardiol"},{"issue":"728","key":"5054_CR26","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/pgmj.62.728.601","volume":"62","author":"AF de Freitas","year":"1986","unstructured":"de Freitas\u00a0AF (1986) The heart in Portuguese amyloidosis. Postgrad Med\u00a0J 62(728):601\u2013605","journal-title":"Postgrad Med J"},{"issue":"4","key":"5054_CR27","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jelectrocard.2007.12.001","volume":"41","author":"JS Chinitz","year":"2008","unstructured":"Chinitz\u00a0JS, Cooper\u00a0JM, Verdino\u00a0RJ (2008) Electrocardiogram voltage discordance: interpretation of low QRS voltage only in the limb leads. J\u00a0Electrocardiol 41(4):281\u2013286","journal-title":"J Electrocardiol"},{"issue":"12","key":"5054_CR28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1016\/j.hrthm.2019.06.006","volume":"16","author":"D Blendea","year":"2019","unstructured":"Blendea\u00a0D, McPherson\u00a0CA, Pop\u00a0S, Ruskin\u00a0JN (2019) Isolated very low QRS voltage in the frontal leads predicts recurrence of neurally mediated syncope. Heart Rhythm 16(12):1862\u20131869","journal-title":"Heart Rhythm"},{"key":"5054_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s12574-020-00508-3","author":"H Tanaka","year":"2021","unstructured":"Tanaka\u00a0H (2021) Efficacy of echocardiography for differential diagnosis of left ventricular hypertrophy: special focus on speckle-tracking longitudinal strain. J\u00a0Echocardiogr. https:\/\/doi.org\/10.1007\/s12574-020-00508-3","journal-title":"J Echocardiogr"},{"issue":"4","key":"5054_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","volume":"13","author":"M Boldrini","year":"2020","unstructured":"Boldrini\u00a0M, Cappelli\u00a0F, Chacko\u00a0L et\u00a0al (2020) Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13(4):909\u2013920","journal-title":"JACC Cardiovasc Imaging"},{"issue":"7","key":"5054_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00059-020-04980-6","volume":"45","author":"R Erbel","year":"2020","unstructured":"Erbel\u00a0R (2020) Aortenstenose \u2013 welche diagnostischen Algorithmen und welche Therapie? Herz 45(7):703\u2013714","journal-title":"Herz"},{"issue":"9","key":"5054_CR32","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ehjci\/jew130","volume":"17","author":"D Bonderman","year":"2016","unstructured":"Bonderman\u00a0D, Agis\u00a0H, Kain\u00a0R, Mascherbauer\u00a0J (2016) Amyloid in the heart: an under-recognized threat at the interface of cardiology, haematology, and pathology. Eur Heart J Cardiovasc Imaging 17(9):978\u2013980","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"5","key":"5054_CR33","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","volume":"12","author":"A Martinez-Naharro","year":"2019","unstructured":"Martinez-Naharro\u00a0A, Kotecha\u00a0T, Norrington\u00a0K et al (2019) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12(5):810\u2013819","journal-title":"JACC Cardiovasc Imaging"},{"issue":"5","key":"5054_CR34","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jcmg.2018.03.029","volume":"12","author":"A Yilmaz","year":"2019","unstructured":"Yilmaz\u00a0A (2019) The \u201cNative T1 versus extracellular volume fraction paradox\u201d in cardiac amyloidosis: answer to the million-dollar question? JACC Cardiovasc Imaging 12(5):820\u2013822","journal-title":"JACC Cardiovasc Imaging"},{"issue":"11","key":"5054_CR35","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala\u00a0S, Ando\u00a0Y, Bokhari\u00a0S et al (2019) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2\u2011evidence base and standardized methods of imaging. J\u00a0Card Fail 25(11):e1\u2013e39","journal-title":"J Card Fail"},{"key":"5054_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","volume":"27","author":"S Dorbala","year":"2020","unstructured":"Dorbala\u00a0S, Ando\u00a0Y, Bokhari\u00a0S et\u00a0al (2020) ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2\u2014Diagnostic criteria and appropriate utilization. J\u00a0Nucl Cardiol 27:659\u2013673","journal-title":"J Nucl Cardiol"},{"issue":"6","key":"5054_CR37","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini\u00a0E, Guidalotti\u00a0PL, Salvi\u00a0F et al (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc\u20113,3\u2011diphosphono\u20111,2\u2011propanodicarboxylic acid scintigraphy. J\u00a0Am Coll Cardiol 46(6):1076\u20131084","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"5054_CR38","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jcmg.2016.06.003","volume":"10","author":"M Haq","year":"2017","unstructured":"Haq\u00a0M, Pawar\u00a0S, Berk\u00a0JL, Miller\u00a0EJ, Ruberg\u00a0FL (2017) Can 99mTc-pyrophosphate aid in early detection of cardiac involvement in asymptomatic variant TTR amyloidosis? JACC Cardiovasc Imaging 10(6):713\u2013714","journal-title":"JACC Cardiovasc Imaging"},{"issue":"10","key":"5054_CR39","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan\u00a0M, Scott\u00a0CG, Kyle\u00a0RA et al (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a\u00a0novel staging system. J\u00a0Am Coll Cardiol 68(10):1014\u20131020","journal-title":"J Am Coll Cardiol"},{"issue":"30","key":"5054_CR40","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","volume":"39","author":"JD Gillmore","year":"2018","unstructured":"Gillmore\u00a0JD, Damy\u00a0T, Fontana\u00a0M et\u00a0al (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart\u00a0J 39(30):2799\u20132806","journal-title":"Eur Heart J"},{"issue":"4","key":"5054_CR41","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s00392-020-01698-7","volume":"110","author":"C Binder","year":"2021","unstructured":"Binder\u00a0C, Duca\u00a0F, Binder\u00a0T et\u00a0al (2021) Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis. Clin Res Cardiol 110(4):532\u2013543","journal-title":"Clin Res Cardiol"},{"key":"5054_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-020-10062-w","author":"V Bistola","year":"2021","unstructured":"Bistola\u00a0V, Parissis\u00a0J, Foukarakis\u00a0E et\u00a0al (2021) Practical recommendations for the diagnosis and management of transthyretin cardiac amyloidosis. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-020-10062-w","journal-title":"Heart Fail Rev"},{"key":"5054_CR43","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1093\/eurheartj\/ehz298","volume":"40","author":"M Emdin","year":"2019","unstructured":"Emdin\u00a0M, Aimo\u00a0A, Rapezzi\u00a0C et\u00a0al (2019) Treatment of cardiac transthyretin amyloidosis: an update. Eur Heart\u00a0J 40:3699\u20133706","journal-title":"Eur Heart J"},{"key":"5054_CR44","volume-title":"Tafamidis (Wildtyp- oder heredit\u00e4re Transthyretin-Amyloidose mit Kardiomyopathie) \u2013 Bewertung gem\u00e4\u00df \u00a7 35a Abs. 1 Satz 11 SGB V","author":"IQWiG-Berichte","year":"2020","unstructured":"IQWiG-Berichte (2020) Tafamidis (Wildtyp- oder heredit\u00e4re Transthyretin-Amyloidose mit Kardiomyopathie) \u2013 Bewertung gem\u00e4\u00df \u00a7 35a Abs. 1 Satz 11 SGB V (Nr.\u00a0916)"},{"key":"5054_CR45","unstructured":"Gemeinsamer Bundesausschuss (2017) Verfahrensordnung des Gemeinsamen Bundesausschusses. https:\/\/www.g-ba.de\/beschluesse\/4421\/. Zugegriffen: 20.08.2020"},{"issue":"5","key":"5054_CR46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11864-020-00738-8","volume":"21","author":"AVS Macedo","year":"2020","unstructured":"Macedo\u00a0AVS, Schwartzmann\u00a0PV, de Gusm\u00e3o\u00a0BM, Melo\u00a0MDT, Coelho-Filho\u00a0OR (2020) Advances in the treatment of cardiac amyloidosis. Curr Treat Options Oncol 21(5):36","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"5054_CR47","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer\u00a0MS, Schwartz\u00a0JH, Gundapaneni\u00a0B, ATTR-ACT Study Investigators, ATTR-ACT Study Investigators (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N\u00a0Engl J Med 379(11):1007\u20131016","journal-title":"N Engl J Med"},{"issue":"1","key":"5054_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13023-017-0726-x","volume":"13","author":"Y Sekijima","year":"2018","unstructured":"Sekijima\u00a0Y, Ueda\u00a0M, Koike\u00a0H, Misawa\u00a0S, Ishii\u00a0T, Ando\u00a0Y (2018) Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm. Orphanet J Rare Dis 13(1):6","journal-title":"Orphanet J Rare Dis"},{"key":"5054_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.carrev.2020.06.005","volume":"22","author":"F Cappelli","year":"2021","unstructured":"Cappelli\u00a0F, Perfetto\u00a0F, Martone\u00a0R, Di Mario\u00a0C (2021) Cardiac amyloidosis in patients undergoing TAVR: why we need to think about it. Cardiovasc Revasc Med 22:109\u2013111","journal-title":"Cardiovasc Revasc Med"},{"issue":"3","key":"5054_CR50","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s10741-017-9601-z","volume":"22","author":"M Sousa","year":"2017","unstructured":"Sousa\u00a0M, Monohan\u00a0G, Rajagopalan\u00a0N, Grigorian\u00a0A, Guglin\u00a0M (2017) Heart transplantation in cardiac amyloidosis. Heart Fail Rev 22(3):317\u2013327","journal-title":"Heart Fail Rev"},{"issue":"4","key":"5054_CR51","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000508262","volume":"143","author":"F Theodorakakou","year":"2020","unstructured":"Theodorakakou\u00a0F, Fotiou\u00a0D, Dimopoulos\u00a0MA, Kastritis\u00a0E (2020) Solid organ transplantation in amyloidosis. Acta Haematol 143(4):352\u2013364","journal-title":"Acta Haematol"}],"container-title":["Herz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05054-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00059-021-05054-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00059-021-05054-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T14:10:34Z","timestamp":1633011034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00059-021-05054-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5054"],"URL":"https:\/\/doi.org\/10.1007\/s00059-021-05054-x","relation":{},"ISSN":["0340-9937","1615-6692"],"issn-type":[{"type":"print","value":"0340-9937"},{"type":"electronic","value":"1615-6692"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"8 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>S.\u00a0Erbel-Khurtsidze, R.\u00a0Seibel, D.\u00a0Moka, K.\u00a0Brandt-Mainz, R.\u00a0Erbel<\/b> und <b>A.\u00a0Lichtenberg<\/b> geben an, dass kein Interessenkonflikt besteht.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}